Kyle Vaughn Laster

737 total citations
34 papers, 447 citations indexed

About

Kyle Vaughn Laster is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kyle Vaughn Laster has authored 34 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kyle Vaughn Laster's work include RNA modifications and cancer (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Kyle Vaughn Laster is often cited by papers focused on RNA modifications and cancer (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Kyle Vaughn Laster collaborates with scholars based in China, United States and South Korea. Kyle Vaughn Laster's co-authors include Zigang Dong, Kangdong Liu, Steven T. Kosak, Dong Joon Kim, Xiaomeng Xie, Ashley Wood, Christina M. Cruz, Paolo Annibale, L. Pang and Megan Parilla and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Oncogene.

In The Last Decade

Kyle Vaughn Laster

34 papers receiving 445 citations

Peers

Kyle Vaughn Laster

ONCOL

PRM

Huiping Guo China

Derek A. Franklin United States

Cristina Andreani Italy

Wenping Zhou China

Kevin J Barnum United States

Tuğsan Tezil Türkiye

Irene Marchesi Italy

Nicole Stark United States

Valentina A. Lakunina Russia

Xianfang Liu China

Huiping Guo China

Kyle Vaughn Laster

320 ×1.1

87 ×1.0

118 ×1.5

ONCOL

36 ×0.7

48 ×1.1

PRM

Citations per year, relative to Kyle Vaughn Laster Kyle Vaughn Laster (= 1×) peers Huiping Guo

Countries citing papers authored by Kyle Vaughn Laster

Since Specialization

Citations

This map shows the geographic impact of Kyle Vaughn Laster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle Vaughn Laster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle Vaughn Laster more than expected).

Fields of papers citing papers by Kyle Vaughn Laster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle Vaughn Laster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle Vaughn Laster. The network helps show where Kyle Vaughn Laster may publish in the future.

Co-authorship network of co-authors of Kyle Vaughn Laster

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle Vaughn Laster. A scholar is included among the top collaborators of Kyle Vaughn Laster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle Vaughn Laster. Kyle Vaughn Laster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Dandan, Ming Jiang, Pan Li, et al.. (2025). CHI-KAT8i5 suppresses ESCC tumor growth by inhibiting KAT8-mediated c-Myc stability. Cell Reports. 44(1). 115135–115135. 1 indexed citations

He, Xinyu, Huifang Wei, Kyle Vaughn Laster, et al.. (2025). FBL promotes hepatocellular carcinoma tumorigenesis and progression by recruiting YY1 to enhance CAD gene expression. Cell Death and Disease. 16(1). 348–348. 1 indexed citations

Song, Mengqiu, Yunqing Zhang, Shihui Liu, et al.. (2024). Targeting TAOK1 with resveratrol inhibits esophageal squamous cell carcinoma growth in vitro and in vivo. Molecular Carcinogenesis. 63(5). 991–1008. 3 indexed citations

Guo, Yaping, Huifang Wei, Xuechao Jia, et al.. (2024). Multi-omics characterization of esophageal squamous cell carcinoma identifies molecular subtypes and therapeutic targets. JCI Insight. 9(10). 2 indexed citations

Zhao, Zhiwei, et al.. (2024). Advancements in therapeutic peptides: Shaping the future of cancer treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1879(6). 189197–189197. 3 indexed citations

Song, Mengqiu, et al.. (2023). Cdc2-like kinases: structure, biological function and therapeutic targets for diseases. Signal Transduction and Targeted Therapy. 8(1). 148–148. 35 indexed citations

Jia, Xuechao, Penglei Wang, Chuntian Huang, et al.. (2023). Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth. Journal of Experimental & Clinical Cancer Research. 42(1). 97–97. 12 indexed citations

Xie, Xiaomeng, Kyle Vaughn Laster, Jian Li, et al.. (2023). OSGIN1 is a novel TUBB3 regulator that promotes tumor progression and gefitinib resistance in non-small cell lung cancer. Cellular and Molecular Life Sciences. 80(9). 272–272. 7 indexed citations

Wang, Zitong, Yu Yin, Wenjie Wu, et al.. (2022). Oxethazaine inhibits esophageal squamous cell carcinoma proliferation and metastasis by targeting aurora kinase A. Cell Death and Disease. 13(2). 189–189. 11 indexed citations

10.

Xie, Xiaomeng, et al.. (2022). Ethyl Ferulate Suppresses Esophageal Squamous Cell Carcinoma Tumor Growth Through Inhibiting the mTOR Signaling Pathway. Frontiers in Oncology. 11. 780011–780011. 8 indexed citations

11.

Zhao, Ran, Xiaorong Fu, Ning Lü, et al.. (2022). Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo. Acta Pharmaceutica Sinica B. 12(11). 4122–4137. 14 indexed citations

12.

Wang, Xiangyu, Xiaomeng Xie, Yuanyuan Zhang, et al.. (2022). Hippocalcin-like 1 is a key regulator of LDHA activation that promotes the growth of non-small cell lung carcinoma. Cellular Oncology. 45(1). 179–191. 13 indexed citations

13.

Xie, Xiaomeng, et al.. (2021). 2,6-DMBQ suppresses cell proliferation and migration via inhibiting mTOR/AKT and p38 MAPK signaling pathways in NSCLC cells. Journal of Pharmacological Sciences. 145(3). 279–288. 5 indexed citations

14.

Zhang, Yuanyuan, Xiaodan Shi, Xiaomeng Xie, et al.. (2021). Harmaline isolated from Peganum harmala suppresses growth of esophageal squamous cell carcinoma through targeting mTOR. Phytotherapy Research. 35(11). 6377–6388. 14 indexed citations

15.

Fu, Xiaorong, Ran Zhao, Goo Yoon, et al.. (2021). 3-Deoxysappanchalcone Inhibits Skin Cancer Proliferation by Regulating T-Lymphokine-Activated Killer Cell-Originated Protein Kinase in vitro and in vivo. Frontiers in Cell and Developmental Biology. 9. 638174–638174. 11 indexed citations

16.

Shi, Xiaodan, Yuanyuan Zhang, Xiaomeng Xie, et al.. (2021). Ipriflavone Suppresses Growth of Esophageal Squamous Cell Carcinoma Through Inhibiting mTOR In Vitro and In Vivo. Frontiers in Oncology. 11. 648809–648809. 4 indexed citations

17.

Jin, Guoguo, Kangdong Liu, Ke Yao, et al.. (2020). Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer. Oncogene. 39(43). 6733–6746. 16 indexed citations

18.

Ma, Xiaoli, Xiaomeng Xie, Bingbing Lu, et al.. (2020). 2,6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo. Journal of Experimental & Clinical Cancer Research. 39(1). 107–107. 15 indexed citations

19.

Neems, Daniel, Kyle Vaughn Laster, Iwona Konieczna, et al.. (2019). Varying levels of X chromosome coalescence in female somatic cells alters the balance of X-linked dosage compensation and is implicated in female-dominant systemic lupus erythematosus. Scientific Reports. 9(1). 16145–16145. 5 indexed citations

20.

Wood, Ashley, et al.. (2015). A beginning of the end: new insights into the functional organization of telomeres. Nucleus. 6(3). 172–178. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact